Healthcare / Medical Care FacilitiesJakarta
$900.00
-45.00 (-4.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-612.2B · quality 56.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.79T
P/E
33.8x
↑EV/EBITDA
12.7x
↑ROE
7.6%
↑Gross Margin
33.8%
↓Debt/Equity
0.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.3%
FCF CAGR
—
FCF margin
-8.6%
FCF / Net income
-1.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.13T · net income $429.55B · FCF $-612.15B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7133.54B | $7133.54B | $6717.18B | $5784.08B | $4901.81B |
| Net Income | $429.55B | $429.55B | $535.94B | $437.35B | $298.60B |
| EBITDA | $1272.66B | $1272.66B | $1345.59B | $1100.75B | $812.54B |
| EPS | 28.40 | 28.40 | 36.11 | 29.73 | 20.29 |
| Gross Margin | 33.8% | 33.8% | 36.3% | 35.6% | 34.9% |
| Operating Margin | 13.2% | 13.2% | 15.4% | 13.5% | 10.5% |
| Net Margin | 6.0% | 6.0% | 8.0% | 7.6% | 6.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.57 | 0.57 | 0.73 | 0.58 | 0.50 |
| Current Ratio | 1.36 | 1.36 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-612.15B | $-612.15B | $-1144.37B | $-271.71B | $-261.27B |
| Returns | |||||
| ROE | 7.6% | 7.6% | 12.0% | 11.3% | 8.7% |
| Valuation | |||||
| P/E | 33.77 | 33.77 | 43.62 | 49.61 | 83.05 |
| EV/EBITDA | 12.66 | 12.66 | 19.30 | 20.99 | 31.70 |
| P/B | 2.40 | 2.40 | 5.25 | 5.61 | 7.21 |
| Growth & Yield | |||||
| Revenue Growth | 6.2% | 6.2% | 16.1% | 18.0% | — |
| EPS Growth | -21.4% | -21.4% | 21.5% | 46.5% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
41.1%
EPS terminal req.
$79.86
Spread vs growth
-62.5%
5Y implied EPS CAGR
27.7%
EPS terminal req.
$96.63
Spread vs growth
-49.1%
10Y implied EPS CAGR
18.5%
EPS terminal req.
$155.62
Spread vs growth
-39.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.3%
Start / end P/E
36.0x → 31.7x
EPS bridge
36.11 → 28.40
Residual
+2.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.